India Launches First Indigenous Bird Flu Vaccine for Chickens
Union Minister Shivraj Singh Chouhan will unveil India's pioneering indigenous inactivated H5N1 vaccine for chickens on November 20, bolstering national biosecurity.
The Cliff News | 18 November 2026
India is set to bolster its defenses against avian influenza with the upcoming launch of its first indigenously developed inactivated H5N1 vaccine for chickens. Union Minister of Agriculture and Farmers Welfare and Rural Development, Shivraj Singh Chouhan, will formally dedicate this crucial vaccine to the nation on November 20 at the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal.
The groundbreaking vaccine targets the H5N1 Highly Pathogenic Avian Influenza (HPAI) virus of Clade 2.3.2.1a, a specific strain that has been responsible for a significant number of bird flu outbreaks in chickens. Its development by ICAR-NIHSAD marks a significant step towards self-reliance in combating this devastating disease.
Protecting Poultry and Economy from Bird Flu
Highly Pathogenic Avian Influenza, commonly known as bird flu, poses a severe threat to the poultry sector. Outbreaks can lead to near 100 per cent mortality among infected birds, resulting in substantial financial losses for farmers due to mass culling and trade restrictions. The economic ramifications extend beyond individual farms, impacting global trade, poultry product prices, and the livelihoods of countless individuals.
Since its first detection in India in 2006, the country has reported over 500 combined outbreaks of H5N1 and H5N8 subtypes. The economic impact of a major bird flu outbreak could be severe, potentially reducing India's GDP growth by as much as 1.5 per cent. Without effective control measures, over 20 per cent of the country's poultry population could be at risk. In the past, outbreaks have inflicted considerable financial damage, with the 2006 event alone causing estimated losses of Rs. 2,200–3,000 crore. A similar outbreak in Manipur previously resulted in losses equivalent to 0.5 per cent of the state's GDP.
Public Health Concerns and the New Vaccine
Beyond economic losses, bird flu also presents a significant public health concern. According to the World Health Organization (WHO), 1,003 human cases of H5N1 avian influenza, including 479 deaths, have been reported globally across 25 countries, with India among them, since 2003. The H5N1 strain, particularly Clade 2.3.2.1a, has not only caused widespread bird flu outbreaks but has also been detected in various animal species, including mammals, and has led to three human cases in recent times.
The development of an indigenous vaccine is therefore critical to mitigate these risks. Currently, no specific commercial vaccine is readily available against the H5N1 virus of Clade 2.3.2.1a circulating in India. The newly developed vaccine by ICAR-NIHSAD aims to fill this void, providing essential protection and reducing the likelihood of transmission from chickens to other animals and humans, thereby safeguarding both the agricultural economy and public health.
